电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Recombinant PTK7 (Cofetuzumab Biosimilar) 抗体

This Humanized 单克隆 antibody specifically detects PTK7 (Cofetuzumab Biosimilar) in FACS 和 in vivo. It exhibits reactivity toward 人.
产品编号 ABIN7795145
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for Recombinant PTK7 (Cofetuzumab Biosimilar) 抗体 (ABIN7795145)

抗原

PTK7 (Cofetuzumab Biosimilar)

抗体类型

Recombinant Antibody

适用

宿主

  • 2
  • 1
  • 1
Humanized

克隆类型

  • 3
  • 1
单克隆

标记

  • 4
This PTK7 (Cofetuzumab Biosimilar) antibody is un-conjugated

应用范围

  • 2
  • 2
  • 1
  • 1
  • 1
Flow Cytometry (FACS), In vivo Studies (in vivo)

质量等级

Research Grade
  • Expression System

    Mammalian cells

    原理

    Cofetuzumab Biosimilar, Human PTK7 Monoclonal Antibody

    产品特性

    What is cofetuzumab biosimilar research grade? Cofetuzumab is a humanized IgG1-kappa monoclonal antibody against PTK7, which is a tumor-associated antigen (TAA) and overexpressed on a variety of cancer cells. Cofetuzumab pelidotin is an antibody-drug conjugate (ADC) composed of cofetuzumab linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. Cofetuzumab biosimilar uses the same protein sequences as the therapeutic antibody cofetuzumab.

    纯化方法

    Protein A or G affinity column

    纯度

    >95 % by reducing SDS-PAGE

    内毒素水平

    < 1 EU per 1 mg of the protein by the LAL method

    免疫原

    Human PTK7
  • 应用备注

    Optimal working dilution should be determined by the investigator.

    限制

    仅限研究用
  • 状态

    Liquid

    浓度

    > 3 mg/mL

    储存条件

    4 °C,-20 °C

    储存方法

    Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
  • 抗原

    PTK7 (Cofetuzumab Biosimilar)

    别名

    Cofetuzumab Biosimilar

    物质类

    Biosimilar
You are here: